WO1999002704A3 - Phosphatase a double specificite et procedes d'utilisation - Google Patents

Phosphatase a double specificite et procedes d'utilisation Download PDF

Info

Publication number
WO1999002704A3
WO1999002704A3 PCT/US1998/014205 US9814205W WO9902704A3 WO 1999002704 A3 WO1999002704 A3 WO 1999002704A3 US 9814205 W US9814205 W US 9814205W WO 9902704 A3 WO9902704 A3 WO 9902704A3
Authority
WO
WIPO (PCT)
Prior art keywords
pten
methods
phosphatase
dual
specifically
Prior art date
Application number
PCT/US1998/014205
Other languages
English (en)
Other versions
WO1999002704A2 (fr
Inventor
Nicholas K Tonks
Michael P Myers
Original Assignee
Cold Spring Harbor Lab
Nicholas K Tonks
Michael P Myers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab, Nicholas K Tonks, Michael P Myers filed Critical Cold Spring Harbor Lab
Priority to AU84794/98A priority Critical patent/AU8479498A/en
Publication of WO1999002704A2 publication Critical patent/WO1999002704A2/fr
Publication of WO1999002704A3 publication Critical patent/WO1999002704A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

L'invention concerne des protéines PTEN, des protéines PTEN modifiées et des molécules d'acides nucléiques codant ces protéines ou ces protéines modifiées. L'invention se rapporte en outre à des procédés de diagnostic et de traitement, par exemple, du cancer de la prostate, qui utilisent des compostions renfermant des PTEN, des PTEN modifiées, ou bien des molécules d'acides nucléiques codant ces PTEN ou ces PTEN modifiées.
PCT/US1998/014205 1997-07-08 1998-07-08 Phosphatase a double specificite et procedes d'utilisation WO1999002704A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU84794/98A AU8479498A (en) 1997-07-08 1998-07-08 Dual specificity phosphatase and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5190897P 1997-07-08 1997-07-08
US60/051,908 1997-07-08
US9098498P 1998-06-29 1998-06-29
US60/090,984 1998-06-29

Publications (2)

Publication Number Publication Date
WO1999002704A2 WO1999002704A2 (fr) 1999-01-21
WO1999002704A3 true WO1999002704A3 (fr) 1999-04-01

Family

ID=26729940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/014205 WO1999002704A2 (fr) 1997-07-08 1998-07-08 Phosphatase a double specificite et procedes d'utilisation

Country Status (2)

Country Link
AU (1) AU8479498A (fr)
WO (1) WO1999002704A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248327B1 (en) 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
WO2000060092A2 (fr) * 1999-04-07 2000-10-12 Ceptyr, Inc. Phosphatase a specificite double dsp-3
AU4367600A (en) * 1999-07-02 2001-01-22 Ceptyr, Inc. Dsp-3 dual-specificity phosphatase
US7078210B2 (en) 1999-07-02 2006-07-18 Ceptyr, Inc. DSP-3 dual-specificity phosphatase
US6284538B1 (en) 1999-07-21 2001-09-04 Isis Pharmaceuticals, Inc. Antisense inhibition of PTEN expression
JP2003507016A (ja) * 1999-08-13 2003-02-25 スージェン・インコーポレーテッド 新規な蛋白質ホスファターゼおよびホスファターゼ関連疾患の診断および治療
AU2001247782A1 (en) * 2000-03-24 2001-10-08 Millennium Pharmaceuticals, Inc. 18221, dual specificity phosphatase and uses thereof
EP1289472A4 (fr) * 2000-05-30 2004-09-08 Advanced Res & Tech Inst Compositions et methodes d'identification d'agents modulateurs de la fonction pten et des mecanismes de la pi-3 kinase
KR20040018598A (ko) * 2002-08-23 2004-03-04 코웰창업투자(주) Ｔａｔ-ＰＴＥＮ 융합 단백질, 이의 제조 방법 및 용도
US20040106141A1 (en) * 2002-11-05 2004-06-03 The Regents Of The University Of California Methods and materials for examining pathways associated with glioblastoma progression
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004074459A2 (fr) * 2003-02-19 2004-09-02 Georgetown University Cellules deficientes en pten et utilisations de celles-ci
CA2777628C (fr) * 2009-10-16 2019-12-03 The University Of British Columbia Compositions d'inhibiteurs de phosphatase et d'homologue de tensine (pten), utilisations et procedes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015686A1 (fr) * 1995-10-23 1997-05-01 Imperial Cancer Research Technology Limited Diagnostic de predisposition au cancer et traitement approprie
WO1998033907A1 (fr) * 1997-01-30 1998-08-06 Board Of Regents, The University Of Texas System Suppresseur tumoral ts10q23.3
WO1998034624A1 (fr) * 1997-02-07 1998-08-13 The Trustees Of Columbia University In The City Of New York Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015686A1 (fr) * 1995-10-23 1997-05-01 Imperial Cancer Research Technology Limited Diagnostic de predisposition au cancer et traitement approprie
WO1998033907A1 (fr) * 1997-01-30 1998-08-06 Board Of Regents, The University Of Texas System Suppresseur tumoral ts10q23.3
WO1998034624A1 (fr) * 1997-02-07 1998-08-13 The Trustees Of Columbia University In The City Of New York Utilisation du gene suppresseur de tumeur p-ten dans le diagnostic et le traitement de cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL - EMHUM2 3 April 1997 (1997-04-03), LI, J. ET AL.: "Human putative protein tyrosine phosphatase (PTEN) mRNA, complete cds.", XP002066159 *
DATABASE EMBL - EMHUM2 3 April 1997 (1997-04-03), STECK, P.A. ET AL.: "Human mutated in multiple advanced cancers protein (MMAC1) mRNA, complete cds.", XP002066161 *
LI, D-M. ET AL.: "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.", CANCER RESEARCH, vol. 57, 1 June 1997 (1997-06-01), pages 2124 - 2129, XP002066157 *
LI, J. ET AL.: "PTEN, a putative tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.", SCIENCE, vol. 275, 28 March 1997 (1997-03-28), pages 1943 - 1946, XP002066155 *
MAEHAMA, T. ET AL.: "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 22, 29 May 1998 (1998-05-29), pages 13375 - 8, XP002088259 *
MYERS, M. ET AL.: "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatse.", PROC.NATL.ACAD.SCI.USA, vol. 94, August 1997 (1997-08-01), XP002088258 *
PAYRASTRE, B. ET AL.: "Phosphoinositide 3-phosphatase segregates from phosphatidylinositol 3-kinase in EGF-stimulated A431 cells and fails to in vitro hydrolyse phosphatidylinositol(3,4,5)trisphosphate.", FEBS LETTERS, vol. 341, 1994, pages 113 - 8, XP002088256 *
STECK, P.A. ET AL.: "Identification of a candidate tumor suppressor gene at 10q23.3 that is mutated in multiple advanced cancers, MMAC1.", NATURE GENETICS, vol. 15, April 1997 (1997-04-01), pages 356 - 363, XP002066156 *
ZHOU, G. ET AL.: "The catalytic role of Cys124 in the dual specificity phosphatase VHR.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 45, 11 November 1994 (1994-11-11), pages 28084 - 90, XP002088257 *

Also Published As

Publication number Publication date
WO1999002704A2 (fr) 1999-01-21
AU8479498A (en) 1999-02-08

Similar Documents

Publication Publication Date Title
WO2001072962A3 (fr) Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique
WO2000028090A3 (fr) Essais diagnostiques du cancer
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO1998037093A3 (fr) Composes permettant l'immunotherapie du cancer de la prostate et procedes concernant leur utilisation
WO1999047674A3 (fr) Composes et methodes therapeutiques et diagnostiques du cancer du poumon
WO2000018914A3 (fr) NOUVEAUX POLYPEPTIDES $i(DKR)
AU4903101A (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
WO2002029086A3 (fr) Sequences d'acide nucleique differentiellement exprimees dans un tissu cancereux
WO1999002704A3 (fr) Phosphatase a double specificite et procedes d'utilisation
RU2001104349A (ru) Композиции и способы для терапии и диагностики рака предстательной железы
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO2000053776A3 (fr) Nouveaux genes humains du type kallikreine
WO1998059040A3 (fr) Sous-unite de telomerase catalytique humaine et son utilisation therapeutique et diagnostique
WO2001018046A3 (fr) Sequences de tumeurs ovariennes et procedes d'utilisation correspondants
DK1082423T3 (da) Cyclin E2-gener og -proteiner
ZA975588B (en) Isolated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof.
WO1997029199A3 (fr) Peptides pour l'antigene prostatique specifique et leurs utilisations
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
WO1999046374A3 (fr) Sequences d'acide nucleique humaines issues de tissus tumoraux prostatiques
MX9806041A (es) Proteina purificada sr-p70.
AU7147898A (en) (dirofilaria) and (brugia) ankyrin proteins, nucleic acid molecules, and uses thereof
WO1999054349A3 (fr) Molecules d'acides nucleiques dermatophagoides, proteines et leurs utilisations
WO2002010388A3 (fr) Molecules du type recepteur de complement c3b/c4b et utilisations de ces molecules
WO2001059120A3 (fr) Molecules de type il-17 et utilisation de ces dernieres

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase